EyePoint (EYPT) Q2 Revenue Drops 44%

EyePoint Pharmaceuticals (NASDAQ:EYPT), a biopharmaceutical company specializing in sustained-release treatments for retinal diseases, reported its second quarter 2025 results on August 6, 2025. The company’s GAAP revenue of $5.3 million missed analyst expectations of $6.65 million, while the net loss per share (GAAP) was ($0.85), compared to the anticipated ($0.82). Revenue (GAAP) fell sharply from the prior year, and expenses rose, largely from advanced clinical trial activity. The quarter demonstrated clear operational progress in its clinical development programs, but the financials underscored the company’s reliance on future success of its lead asset, DURAVYU™, for both revenue stability and long-term viability. Source: Analyst estimates for the quarter provided by FactSet. EyePoint focuses on developing sustained-release drug treatments for serious eye diseases using its Durasert® technology platform. Its lead product, DURAVYU™, is designed to treat vision-threatening retinal diseases, such as wet age-related macular degeneration (wet AMD), by releasing a medication over several months with a single injection.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool